Colette Lipp

Senior Director, Oncology and Hematology Business Development at Merck

Speaker

Colette is a Senior Director of Global Business Development, Oncology and Hematology at Merck KGaA, Darmstadt, Germany. As part of Merck's Business Development team, she is responsible for establishing new collaborations and executing transactions, specifically in the oncology and hematology space.

During her career, she has led a variety of negotiations including in-licensing Jiangsu Hengrui Pharmaceutical Co. Ltd's PARP1 inhibitor with option to their Claudin18.2 ADC and leading Abbisko Therapeutics' pimicotinib, as well as the the repatriation of Bavencio (avelumab) from Pfizer Inc. to Merck. She has also led three targeted protein degradation transactions, with C4 Therapeutics Inc., Amphista Therapeutics and Proxygen GmbH, allowing Merck to expand its presence in the protein degradation field.

Colette holds a DPhil in Biochemistry from the University of Oxford, an MSc. in Molecular and Biological Chemistry from Ecole Polytechnique Federale de Lausanne (EPFL) and BSc. from the Australian National University.